Mayo Labs PRESIDENT: One oversight can make us work

The diagnosis and detection of new coronary diseases is the focus of many people's attentionIn the early stages of infection, we can find the confirmed patient for the first time, isolate it and treat it, and after the infection, we can find individuals who already have antibodies in their bodies that may be immune to the new coronavirusSuch testing is essential, whether it's providing potential plasma therapies or in order to restart the economy as quickly as possible16 evening held the drug Mingkangde "together with the heart" of the new crown forum, Mayo Clinic Laboratory President DrWilliam Morice and Aetion CEO Carolyn Magill on the topic of diagnosis and testing began a dialogueThe Forum attracted nearly 2,500 participants from 37 different countries and regions on the Zoom platformAt the same time, the forum's Phoenix Network live channel viewers reached 112,000Believe that the diagnostic experience from the first line, to every audience has a revelationCarolyn Magill: It's great to be here to discuss with youBill, you've been working at the Mayo Clinic for over 30 yearsAs president of the Mayo Clinic Lab, what have you observed in this outbreak and what is the priority?DrWilliam Morice: Thank you to the organizers for inviting meIt has been 50 years since the Mayo Clinic Laboratory was establishedAs part of the Mayo Clinic, it is to open clinical laboratories to the public so that people can be testedSince the outbreak, the Mayo Clinic Laboratory has provided testing services to the public as soon as possible, in accordance with the needs of patients and doctorsBut at the same time, we also face challenges such as how to quickly launch testing on a global scale or improve access to these detection technologies our initial focus was molecular detection By constantly communicating with the drug, we realized at an early stage that there would be a lot of testing needs, so we started developing our own testing tools in February By March, as the outbreak continued to change, we continued to provide testing with the entire industry I think this also shows the advantages of clinical laboratories in guiding treatment Clinical laboratories should make their own voices in terms of what different tests can do Carolyn Magill, : I'm in Brooklyn, New York, where a lot of people have no way to test Can you talk about the challenges? Where do they come from and how can they be resolved? Dr William Morice: Partly because of the fragmentation of the health care system For example, many clinical trials focus on outpatient testing, but in the outbreak, we also need to do a lot of inpatient testing Because of fragmentation, it is difficult to quickly deploy relevant detections on a large scale In addition, there are some problems in the supply chain, which can not meet the demand for new diagnostic tools for rapid transportation in the new corona outbreak This may be an important lesson for the future Ms Carolyn Magill: The Mayo Clinic is currently conducting serological testing and plasma treatment Can you share the progress with us? Dr William Morris, President of the 's Center for the Mayo Clinic Dr William Morice: The Mayo Clinic and many other laboratories are developing serological testing There is a slight difference between these tests, some using only IgG and others using other antibody types, but are intended to see how the new coronavirus is responded to We are more focused on IgG On the one hand, we are thinking about specificity On the other hand, we also hope that these tests will lead to the discovery of potential plasma donors for our plasma treatment programs in the United States, especially in Minnesota, where the Mayo Clinic is headquartered, our need is to slow the rate of case growth as quickly as possible So in crisis management, we need a combination of many different tests We need molecular detection technology, we need serological testing, we need to find people who are already exposed to the virus We need to know how quickly different groups can gain group immunity, and we need to find potential plasma donors If we can use the detection techniques to find infected people and find early-recoverers and get their plasma, we can control them where the outbreak has broken out Carolyn Magill: Do you know how often immunity occurs after an infection? For example, how often will antibodies appear? Dr William Morice: Everyone wants to know the answer to this question, because it affects many public health policies and finds people who are relatively safe to start working again In the early days of the outbreak, there was a clear imbalance between supply and demand Now we need to focus on both molecular testing and serological testing For serological testing, we need to combine molecular testing to understand how viruses and hosts interact so that we can come to a stronger conclusion about what serotonin (note: the ability to detect antibodies) means for individual protection and what it means to society This aspect is very attractive Before we can restart our lives, we need to balance our personal risks with our stakes in society Carolyn Magill, : Let's talk about international cooperation Now that we've seen practices in many different countries, what experiences do you want to share with the world and what do you want to learn from other countries? Dr William Morice: As Jim says (see today's Drug Mingcon front report), global collaboration in data sharing and data modeling is critical in the face of pandemics We need to take stock of the experience and lessons learned and understand what this means for the rest of the world's vires countries Some of the important lessons come from analysis using statistical methods, such as a study that lets us know how the new coronavirus starts in northern Italy and spreads across the country This kind of analysis allows us to better understand the effects of different variables from a statistical perspective I learned two things from it First, reducing social mobility can weaken the virus and slow the rate of outbreaks; In my opinion, this is the most important variable It's about how the epidemic will develop, and how we see the current diagnostic techniques and the means of prevention and control the population of New York is much larger than Minnesota's How we use detection techniques, how to model, how to control infections, may be different in each state This involves how large the population is at risk, how many people have been exposed to the virus, and the specific need for detection, how early isolation is carried out, and how to reduce exposure to high-risk populations Carolyn Magill: Our online audience also asked a lot of questions, and they wanted to know exactly what they could do Cooperation from different organizations is critical, do you have any suggestions for them? , Dr William Morris: I'd like to make two points The first point is that at the moment, diagnostic laboratories need a systematic approach to learn from testing We need industry-wide efforts to generate useful information and more insightinto into new coronaviruses, the interaction of viruses with humans, and immunology This is the first point Another point is to expose the data and collaborate so that the industry knows that the conclusions we draw from it are safe and accurate so we need to generate high-quality data, analyze it, and model it based on specific populations It's like developing individual drugs for people in different places It's very expensive to test everyone We want to know what happened in Minnesota, where the cost of testing results is very high So what we need is reasonable sampling, data analysis and sharing in fact, in the early days of the outbreak, most of the cooperation we did was more traditional, such as manufacturing But now, I think, we need some less traditional ways of working together to see how data is used and how to build models that are transparent enough If we don't have these models, we won't be able to test some assumptions and don't know what will happen to a particular population Where the risk of infection is high, transparent data and modeling based on data are critical Carolyn Magill: Can you share how the Mayo Clinic can promote cooperation? These experiences may also be critical to other organizations , Dr William Morice: As part of the health care system, we have a center to coordinate all our day-to-day work In the early stages of the outbreak, we had to reduce some activities to ensure that when a large-scale outbreak hit, we had the resources to take care of those with serious illnesses We know that when this happens, a significant proportion of patients will need intensive care The prognosis of intensive care is all about how we care for and manage these patients Clinical testing can play an important role in this Through testing, we can know who is at the highest risk in hospital and who has been exposed to the virus at this time, we look forward to re-opening our daily medical work In the outbreak, medical staff have been hit hard, and many of the hospitals that receive outpatients have closed due to financial problems We need to find a way to restart the health care system quickly If this is a long-term outbreak, the last thing we want is the shutdown of the health care system many patients need surgery or an organ transplant, which has been delayed When we can control the mortality rate of new coronal outbreaks, we need to quickly open up the health care system to provide the care needed by those who do not have new coronal diseases This requires some balance I think we need to talk openly about these issues: How do we make sure the operating room is sterile? Will there be any change in surgery during the outbreak? These things have not been considered before, but they have a big impact on the health care system All of these issues apply globally, and we need to focus on them as soon as possible Ms Carolyn Magill, Ceo, , Ms Carolyn Magill: There's a lot of argument that we need diagnostic techniques or vaccines to restart the economy What do you think of this? , Dr William Morice: We're also concerned about that From the testing laboratory's point of view, we need to think about more than the test itself, because we don't understand the relationship between viruses, individuals, groups, and population immunity Early studies have shown that even patients with serum conversion can experience a virus drop-off within a few days or even a week We need to understand what this means for diagnostic screening and ensure that any decision aimed at restarting the economy is guided by clinical laboratories This requires us to continue our research and share data in order to draw stronger conclusions about the immunity of the population but I think it's challenging in the early stages of infection Although the sensitivity of analytical tests is high, the sensitivity of clinical tests is relatively low for reasons such as sampling This is a gap on our way back to the economy Only other innovative detection technologies can fill this gap Take the temperature-measuring gun as an example, the characteristics it detects are actually lagging behind We need to develop innovative diagnostic techniques that can be detected early in individual exposure to viruses You know, even in low-risk places, as long as there's a communicator, we can get rid of it No one wants to see such a thing happen So I'm also looking at other laboratory tests to make sure we make the right choice Carolyn Magill: Thank you very much for your sharing In the end, do you have any suggestions for the industry? Dr William Morris: The main things we've discussed I would like to conclude that we need to realize that this is a global crisis, that global solutions are needed and that we need proactive cooperation Our ultimate goal is to eradicate the virus completely and truly control the pandemic Unfortunately, isolation alone does not appear to be sufficient to wipe out the virus completely So we need to think more creatively about the cooperation of the whole industry This is not just in response to the new crown outbreak, but also in response to industry-wide challenges such as fragmentation, data analysis and sharing finally, we also need a blueprint for action so that we don't get pushed back every time Every time a country is attacked by a new coronavirus, it seems to be dealing with a whole new virus We need a global community of healthcare and biotechnology industries to come together I think we're going to have other epidemics When the global pandemic re-emerges, we can respond in a more coordinated way Carolyn Magill: Thank you very much for your insight and hope that these good suggestions will help the industry move forward thanks for the support of partners such as Pharmaceutical Bio, Morgan Stanley, Goldman Sachs, Huatai Securities, Huaxing Capital, UBS Group, Qiming Ventures, Frost Sullivan, Johnson and Johnson Innovations, Deloitte, Zoom, BioCentury, Ali Health, Sina Pharma, etc.